|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||1.69 / 14.81|
The company has generated revenues from the lots of newly manufactured Ampligen
First patient treated in the Netherlands
TheStreet's biotech columnist offers his own report card on biotech stocks.
Conference Call Scheduled for Tuesday, November 15, 2016 at 11:00 AM EST
Recent Articles on Hemispherx Biopharma by BioWorld and Pink Sheet Posted to Corporate Website
CEO Says Series of Coordinated Settlements Should Allow the New Management Team to Focus Exclusively on the Company's Long-Term Commercial, Research and Financial Objectives
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.